Provided By GlobeNewswire
Last update: Aug 1, 2023
BURLINGTON, Mass., Aug. 01, 2023 (GLOBE NEWSWIRE) -- Minerva Neurosciences, Inc. (Nasdaq: NERV), a clinical-stage biopharmaceutical company focused on the development of therapies to treat central nervous system disorders, today reported business updates and financial results for the second quarter ended June 30, 2023.
NASDAQ:NERV (2/21/2025, 8:00:01 PM)
1.82
-0.02 (-1.09%)
Find more stocks in the Stock Screener